Histologically, the adventitial layer is thickened with neovessels sprouting off the vasa vasorum networks. In the aorta, T cells and macrophages can accumulate around microvessels, and histiocytes and T cells form granulomatous infiltrates in the media. Vascular smooth muscle cell dropout leads to medial damage and thinning of the muscular layer. The lamina elastic interna, which separates the media from the intima, is fragmented, granting access for mesenchymal cells migrating toward the intima. The intimal layer is expanded, causing luminal stenosis/occlusion with the vascular lumen of arteries often reduced to a pinhole lesion. 
G iant cell arteritis (GCA) is a granulomatous vasculitis typically presenting with intramural infiltrates of T cells, highly activated macrophages, and multinucleated giant cells. 1 Wall-residing T cells are composed of multiple functional lineages, for example, Th1, Th17, Th9, and Tfh cells, compatible with unopposed T-cell activation. 9, 10 In line with this model, a defect in the immunoinhibitory PD-1 (programmed cell death protein-1) checkpoint has been reported in patients with GCA. 6 Low expression of the inhibitory ligand PD-L1 (programmed cell death ligand-1) on antigen-presenting cells is paired with high expression of PD-1 in lesional T cells, compatible with insufficient suppression of peripheral T-cell immunity.
The inflamed arterial wall is rich in IFN (interferon)-γ, leading to profound macrophage activation, 11, 12 which is complemented and modulated by tissue-intrinsic signals. Tissue macrophages produce a broad spectrum of effector molecules (chemokines, cytokines, growth factors, enzymes, etc) and display a territorial distribution. 13 Medial macrophages produce VEGF (vascular endothelial growth factor), FGF (fibroblast growth factor), and PDGF (platelet-derived growth factor), as well as MMPs (matrix metalloproteinases). MMP-2 and MMP-9 may contribute to matrix degradation; for example, the lamina elastic fragmentation. 14 
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Novelty and Significance
What Is Known?
• Giant cell arteritis is a vasculitis of medium and large arteries, including the aorta and its major branches.
• In giant cell arteritis, macrophages and CD (cluster of differentiation) 4 + T cells invade the vascular wall and trigger a maladaptive response to injury, causing luminal occlusion and tissue ischemia.
• MMPs (matrix metalloproteinases) are suspected to contribute to vessel wall destruction.
What New Information Does This Article Contribute?
• Circulating monocytes use MMP-9 to penetrate through engineered endobasement membranes built from type IV collagen. • In the vasculitic tissue lesions, MMP-9 production was essentially limited to macrophages and multinucleated giant cells.
• In chimeric mice, in which vasculitis was induced in human arteries, antibody-mediated blocking of MMP-9 activity was highly efficient in suppressing wall inflammation and disabling downstream pathogenic events, such as intimal hyperplasia and microvascular neoangiogenesis.
• Recombinant human MMP-9 injected into the humanized mice exacerbated vasculitis.
• Systemic delivery of N-acetyl-proline-glycine-proline-a matrikine produced by MMP-9-mediated gelatinolysis-had limited vasculitogenic effects.
In this study, we have examined how MMP-9 contributes to the pathogenesis of medium and large vessel vasculitis. Unexpectedly, we found that MMP-9 was not only aberrantly expressed in vascular wall-residing macrophages and giant cells but was the dominant MMP produced by circulating monocytes and monocyte-derived macrophages, extending the enzyme's pathogenic role beyond tissue remodeling in the vasculitic lesions. MMP-9 enabled patients' monocytes to penetrate through engineered endobasement membranes, mimicking the process of extravasation from the circulation into the tissue. Notably, patients' CD4+ T cells were completely dependent on MMP-9 + monocytes to pass through endobasement membranes. Taken together, MMP-9 emerges as a key gatekeeper enzyme controlling the access of inflammatory cells to the vascular wall and appears critical in breaking the artery's immunoprivilege. Therapeutic targeting of MMP-9's enzymatic activity could simultaneously interfere with multiple disease processes to suppress vasculitis.
MMP-9 is highly expressed in the granulomas of inflammatory bowel disease, 22 enables neuroinflammation, and is considered critically important in tumor invasion and metastases formation. 23 The enzyme has been identified as a key molecule in granuloma formation after mycobacterium tuberculosis infection. 24 We found that macrophages from patients with GCA are programed to produce high amounts of pro-MMP-9. The bias toward MMP-9 production was already evident in the patients' circulating monocytes. Patient-derived monocytes outperformed healthy monocytes in passing through artificial basement membranes built from collagen IV. Most remarkably, neither healthy nor patient-derived CD4 + T cells could penetrate through the collagen IV barrier. However, when accompanied by MMP-9-producing monocytes, T cells rapidly invaded the matrix. We examined the clinical relevance of this MMP-9-dependent breach of the vessel wall immunoprivilege in a human artery-SCID (severe combined immunodeficiency) mouse model of vasculitis. Blocking MMP-9's enzymatic activity had profound antivasculitic effects, suppressing multiple pathogenic domains. Anti-MMP-9 prevented inflammatory cell recruitment into the vessel wall, diminished inflammationinduced neoangiogenesis, and prevented lumen-compromising intimal hyperplasia. Systemic delivery of rMMP-9 (recombinant MMP-9) into chimeric mice confirmed that the protease is needed to establish and sustain inflammatory infiltrates and is engaged in maladaptive repair processes. These data identify MMP-9-producing monocytes as a critical checkpoint in the pathogenesis of vasculitis, implicating them in controlling access to the protected tissue niche of the vascular wall.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request at cweyand@stanford.edu.
Patients and Tissue Samples
Blood samples were obtained from 58 patients with GCA. A diagnosis of GCA was based on typical histological findings. Demographic characteristics of the patients with GCA are presented in the Table. Noninflamed and inflamed temporal arteries were collected from diagnostic biopsies, and GCA-affected aortic samples were obtained from aortic repair surgeries of patients with GCA. Normal human aorta, temporal, and axillary arteries were donated by organ donors. Demographically matched healthy individuals were recruited from the Stanford Blood Bank Research Program. Patients with preexisting diagnoses of cancer, autoimmune disease, or chronic viral infection were excluded.
Statistical Analysis
All statistical analyses were performed using Prism software (version 7; GraphPad Software, La Jolla, CA). All data were evaluated for normality by D'Agostino-Pearson omnibus normality testing. For data exhibiting a normal distribution, statistical significance was calculated by the unpaired or paired 2-tailed Student t test as appropriate. For analysis of data that were not normally distributed, the Mann-Whitney U test was applied. When comparing multiple groups, 2-way ANOVA was used. Correlation was calculated with Pearson analysis. P values of <0.05 were considered significant. To adjust for multiple testing and control the false-discovery rate at the 0.05 level, the BenjaminiHochberg step-down procedure was applied as appropriate.
Study Approval
The study was approved by the institutional review boards, and written informed consent was obtained from all participants as appropriate.
An expanded Materials and Methods section is available in the Online Data Supplement.
Results

Vasculitic Lesions in GCA Are an MMP-9-Rich Environment
Vasculitic infiltrates in GCA-affected arteries contain MMP-2 + and MMP-9 + cells, 14 mostly localized in the inflamed media. Comparative tissue transcriptome analysis in GCA + temporal arteries and nonvasculitic control arteries confirmed that MMP-9 mRNA was 8-to 10-fold enriched in temporal arteritis ( Figure 1A ). Immunohistochemical staining of pro-MMP-9 ( Figure 1B ) provided information about the localization and the cellular origin of the protease. Cells staining positive for pro-MMP-9 accumulated in the media and proximal neointima ( Figure 1B) . Often, pro-MMP-9 + cells were arranged in a radial pattern, suggestive for the migration of such cells toward the vascular lumen. Dual-color immunohistochemistry assigned pro-MMP-9 to CD68 + cells ( Figure 1C ), identifying macrophages as the major cellular source. In the vasculitic lesions, CD68 neg cells, for example, vascular cells contributed minimally to MMP-9 production. In an alternative immunostaining approach, anti-pro-MMP-9 antibodies were paired with anti-PU.1 antibodies (Figure 1D through 1H + cells were distributed in the intima, often adjacent to the internal elastic membrane and within the proximal medial layer. Endothelial cells (EC) were consistently negative for pro-MMP-9. Rare pro-MMP-9 + PU.1 neg cells in the media raised the possibility that infrequent vascular smooth muscle cells may produce pro-MMP-9, but staining was consistently faint. As expected, the granulomatous lesions contained PU.1 + pro-MMP-9 neg macrophages. Most multinucleated giant cells had intense cytoplasmic staining for pro-MMP-9. Staining patterns were similar in GCA-affected aorta ( Figure 1G and 1H) , where pro-MMP-9
+ histiocytes were grouped around medial inflammatory foci. As expected, abundance of MMP-9 transcripts in the vasculitic arteries was associated with upregulation of tissue inhibitors of metalloproteinase mRNA (Online Figure I) .
To understand whether macrophages in patients with GCA are prone to produce pro-MMP-9, we generated macrophages from circulating CD14 + precursor cells. 25 Multiplex analysis for MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, and MMP-12 transcripts in macrophages generated from patients with GCA and age-matched healthy controls detected 15-fold higher levels of MMP-2 mRNA and 4-fold higher levels of MMP-9 mRNA in patient-derived cells ( Figure 1I ). GCA macrophages also produced more MMP-7 mRNA. Notably, the 5 remaining MMPs were indistinguishable in control and GCA macrophages. The differences for MMP-2 and MMP-9 remained statistically significant after adjustment for multiple testing. MMP-2 and MMP-3 cleave the propeptide from the 92-kDa pro-MMP-9 to release the 82-kDa enzymatically active enzyme, 19 enabling patient-derived monocytes and macrophages to activate MMP-9 in situ.
We examined whether the bias toward MMP-2 and MMP-9 overproduction was present in CD14 + precursor cells or was acquired during macrophage differentiation ( Figure 1E ). Profiling of freshly isolated monocytes yielded a similar signature of MMP transcript expression, with patient-derived monocytes being distinguishable from healthy monocytes by the high expression of MMP-2 and MMP-9 mRNA. + monocyte subpopulations failed to phenotypically differentiate patients with GCA and age-matched controls (Online Figure II) .
To examine whether the altered functional state of patientderived monocytes was reflective of broad cellular activation, we quantified cysteinyl cathepsin transcripts (Online Figure  III) . Like MMPs, cathepsins degrade ECM and participate in vessel remodeling. 26 RT-PCR-based quantification of mRNA for 5 members of the cathepsin family yielded similar concentrations in GCA and control monocytes and macrophages (Online Figure III) .
These data identified both circulating monocytes and tissue macrophages from patients with GCA as a potential source of MMP-9. Although MMP-9 + macrophages may participate in vessel wall destruction, the potential role of MMP-9 + monocytes raised the question of how extralesional, circulating cells contribute to MMP-9-dependent pathogenic events outside of the vessel wall lesions.
MMP-9 + Monocytes Enable T-Cell Invasion Through the Basement Membrane
The major cellular components of the vasculitic lesions are CD4 + T cells and macrophages, both of which need to penetrate through the basement membrane of the adventitial vasa vasorum to invade the artery's wall. Multiple matrix proteins contribute to basement membranes, condensed matrix layers separating capillaries from surrounding connective tissue, but reticular collagen IV fibrils form the lamina densa of the endobasement membrane. 27 Collagen IV is a well-established substrate of MMP-9. 17 We built an artificial basement membrane by layering type IV collagen over type I collagen ( Figure 2A ) and tested whether monocytes and CD4 + T cells from patients with GCA could overcome this barrier ( Figure 2B and 2C). Monocytes were able to penetrate through the collagen layers. After 24 hours, 4000 healthy monocytes and 7000 GCA monocytes had reached the lower chamber. In contrast, healthy and patient-derived CD4 + T cells failed to pass through the collagen gel.
To understand whether CD4 + T cells depend on proteaseproducing monocytes to leave the capillary and invade into surrounding tissue space, we isolated monocytes and CD4 + T cells from patients and controls and placed them on top of the artificial basement membrane. If accompanied by monocytes, CD4 + T cells were able to overcome the barrier. Within 24 hours, 26% of the healthy T cells and 44% of the GCA T cells passed through the collagen layers ( Figure 2D ). To test whether the invasiveness of monocytes and T cells was dependent on MMP-9, we applied GS-5745-a monoclonal antibody that functions as an allosteric MMP-9 inhibitor and blocks both pro-MMP-9 activation and active MMP-9 catalysis. 28, 29 In the presence of GS-5745, T-cell migration through type IV collagen was reduced by 66% in healthy T cells and 47% in GCA T cells.
Blocking MMP-9 Ameliorates Vascular Inflammation
To examine whether MMP-9's enzymatic activity is required for the induction and maintenance of vasculitis, we exploited a human artery-SCID-mouse model in which wall inflammation is induced in human vessels engrafted into immunodeficient mice that are immunoreconstituted with peripheral blood mononuclear cells (PBMC) from patients with GCA. 5, 6 Chimeric mice carrying vasculitic human arteries received anti-MMP-9 or isotype control antibody during a 2-week treatment course ( Figure 3) . Histology of explanted arteries demonstrated that inhibiting MMP-9 activity profoundly affected the vasculitic process ( Figure 3A ). Control-treated vasculitic arteries had dense inflammatory infiltrates penetrating all wall layers, medial smooth muscle cells were destroyed, and the elastic lamina was fragmented ( Figure 3A ). Anti-MMP-9 treatment reduced the inflammatory infiltrates and protected from wall destruction ( Figure 3A ). Antibody injection diminished TCR (T-cell receptor) transcripts to about one-third ( Figure 3B ). Immunostaining for the T-cell marker CD3 allowed the enumeration of wall-residing human T cells ( Figure 3C and 3D). In 10 arteries treated with control IgG or anti-MMP-9, median numbers of lesional CD3 + cells declined from 106 to 49 cells per high-power field ( Figure 3D ). Anti-MMP-9 therapy markedly reduced the T-cell infiltrates in 9 of 10 arteries in the study. We used tissue transcriptome analysis of artery grafts to compare cytokine profiles produced by vasculitogenic cells. In anti-MMP-9-treated tissues, expression of the macrophage marker CD163 and the macrophage products IL (interleukin)-6 Figure 1 . MMP (matrix metalloproteinase)-9-producing monocytes and macrophages in giant cell arteritis (GCA). A, Biopsies from GCA-affected temporal arteries and from noninflamed arteries were processed for quantification of MMP-9 transcripts by RT-PCR (reverse transcription polymerase chain reaction). Mean±SEM from 10 tissue samples. B, Immunostaining of tissue sections from GCA temporal arteries. Pro-MMP-9, brown (scale bar=100 μm). C, Dual-color immunostaining of GCA-affected temporal artery sections. Pro-MMP-9, green; macrophage marker CD (cluster of differentiation)-68, red; Pro-MMP-9 + CD68 + cells, yellow (scale bar=100 μm). D-F, Dual-color immunostaining of GCA-affected temporal artery sections. Pro-MMP-9, red. Macrophage marker PU.1, nuclei dark grey. E and F, Pro-MMP-9 + PU.1 + macrophages and multinucleated giant cells along the fragmented lamina elastica (magnification ×400). G and H, Dual-color immunostaining of pro-MMP-9 (red) and PU.1 (nuclei dark grey) in tissue section from GCA aortitis showing granulomatous infiltrate with multinucleated giant cells surrounding necrotic medial layer (G, magnification ×100; H, magnification ×400; scale bar=100 μm). (Continued ) and IL-1β declined significantly ( Figure 3E ). Tissue TNF (tumor necrosis factor)-α production remained unaffected. The T-cell effector cytokines IFN-γ and IL-21 were particularly sensitive to MMP-9 inhibition ( Figure 3E ), whereas lowabundant IL-17 transcripts were unchanged. To connect cytokine gene expression data with T-cell effector functions, we extracted T cells from the artery explants and analyzed cytoplasmic cytokine stores by flow cytometry (Figure 3F through 3H). Anti-MMP-9 treatment reduced the number of tissue-residing T cells by 65%. IFN-γ-producing Th1 cells accounted for 20% of the T-cell infiltrate, and this was unchanged after MMP-9 inhibition. About 10% of tissue-infiltrating T cells produced IL-21, functionally resembling follicular helper T cells. Again, the proportion of IL-21-producing T cells remained stable in the GS-5745-treated grafts. Thus, blocking MMP-9 activity markedly reduced the migration of T cells into the vascular wall, but it did not alter the distribution of functional T-cell subsets.
In summary, enzymatically active MMP-9 is required to support the formation of vasculitic lesions and regulates the recruitment of tissue-resident T cells and macrophages. MMP-9 functions as a gatekeeper controlling innate and adaptive immune responses in the tissue niche.
MMP-9 Enzymatic Activity Is Required for Intimal Hyperplasia and for the Formation of Microvessels
GCA's clinical manifestations are a consequence of intimal hyperplasia, luminal stenosis/occlusion, and downstream tissue ischemia. Mechanisms leading to intimal hyperplasia are insufficiently understood, but recent data suggest a direct role of vasculitogenic T cells in accelerating intimal thickening. 6 To quantify the process of intimal hyperplasia, we determined intimal thickness by measuring the distance between the intimal endothelial layer and the lamina elastic interna ( Figure 4A ). In noninflamed arteries, the intima consists of 1 to 3 cell layers. In control-treated vasculitic arteries, the intima expanded to >10 cell layers ( Figure 4A ). In vessels with densely packed inflammatory infiltrates, the elastic lamina was essentially cleaved into fragments. Treatment with anti-MMP-9 prevented destruction of the elastic lamina and maintained the organization of the intima. Quantification of intimal thickness in 10 arteries exposed to either anti-MMP-9 or isotype control yielded an average of 120 μm for the vasculitic vessels and 55 μm after blocking MMP-9 ( Figure 4B ). Expansion of the intima was suppressed in every artery enrolled into the study.
A second important component of the vasculitic process and the wall's inflammation-induced remodeling is the induction of newly formed microvessels, particularly in the adventitia. 6 Besides promoting adventitial thickening, neoangiogenesis provides a microvascular niche that gives instructive cues to interacting immune cells. 5 Neovessel formation in the arterial wall was quantified by dual color-staining for the endothelial marker CD31 and the smooth muscle cell marker α-SMA (α-smooth muscle actin). 30 In explanted arteries with transmural vasculitis, immunostaining revealed an average of 30 CD31
+ α-SMA + structures per high-power field ( Figure 4C  and 4D ). Microvessel density significantly decreased with anti-MMP-9 therapy. All 10 arteries examined in this experiment responded with inhibition of neoangiogenesis, with a reduction to 15 CD31 + α-SMA + microvessels per high-power field ( Figure 4C and 4D) .
To explore whether the proangiogenic function of MMP-9 was related to the presence of growth factors, we quantified VEGF, PDGF, and FGF transcripts previously described elevated in GCA lesions. 31, 32 Transcript levels for all 3 growth factors seemed dependent on MMP-9 activity and were significantly lower after antibody-mediated MMP-9 inhibition ( Figure 4E ). These data implicated MMP-9 in 2 major pathways of inflammation-induced vessel wall remodeling: mobilization of ECs to build new microvascular networks and mesenchymal cell mobilization to form hyperplastic neointima.
rMMP-9 Exacerbates Vascular Inflammation
To better understand how MMP-9 affects vessel wall infiltrates and wall remodeling, we designed an approach to directly test the enzyme's role in the assembly of inflammatory infiltrates and in shaping vasculitogenic immunity. For these experiments, we generated enzymatically active rMMP-9 and injected the enzyme intraperitoneally into the chimeric mice.
Two controls were included in the experiments: vehicle and an enzymatically inactive form of MMP-9. Pilot experiments guided the dosing to avoid toxic side effects. For 2 weeks, the mice received 600 μg of enzymatically inactive form of MMP-9 or 600 μg rMMP-9.
Histology of the explanted human arteries demonstrated marked exacerbation of vasculitis in the rMMP-9-treated hosts ( Figure 5A ). The entire wall was thickened, occupied by dense cellular infiltrates. To determine whether the wall lesions in MMP-9-exposed arteries contained higher T cell numbers, tissue transcriptomes were analyzed for TCR transcripts, and tissue-resident T cells were quantified by immunohistochemistry ( Figure 5B through 5D) . TCR transcripts and numbers of CD3 + T cells were higher after rMMP-9 injection. In 7 of 8 arteries, T-cell recruitment/retention was more robust in the presence of excess MMP-9 ( Figure 5D ). Increased abundance of T cells in the vascular wall was associated with a parallel rise in the macrophage marker CD163. The profile of tissue cytokines that was responsive to MMP-9 injection included IL-1β, IL-6, IFN-γ, and IL-21 ( Figure 5E and 5F), resembling the pattern encountered in anti-MMP-9-treated chimeras ( Figure 3E ). Tissue production of TNF-α and IL-17 was unaffected by excess MMP-9.
These data supported the concept that MMP-9, even when delivered systemically, has vasculitogenic functions and promotes the formation of panarteritic infiltrates delivering abnormal innate (IL-1β and IL-6) and adaptive (IFN-γ and IL-21) immune responses.
rMMP-9 Promotes Intimal Hyperplasia and Neoangiogenesis
Systemic delivery of MMP-9 had direct impact on the arrangement of tissue-invasive T cells and macrophages in the engrafted human artery. Morphological analysis of the MMP-9-treated arteries focused attention on 2 wall regions: the enlarged adventitia and the hyperplastic neointima ( Figure 6A ). Intimal thickness expanded by 47% from an average of 90 μm in control arteries to an average of 130 μm in MMP-9-oversupplied arteries ( Figure 6B ). The injected MMP-9 promoted almost complete lamina elastic digestion and increased neointimal cellular density to 12 to 15 layers.
Rapid neoangiogenesis and increased numbers of microvascular lumina were the underlying mechanism driving adventitial thickening after MMP-9 delivery ( Figure 6C ). Every arterial graft responded to surplus MMP-9 with robust neoangiogenesis. Newly formed microvessels were quantified by CD31 + α-SMA + immunostaining ( Figure 6C ). Microvascular density increased from 23 to 38 per high-power field ( Figure 6D ), confirming MMP-9's critical role in enabling the sprouting of new blood vessels in the inflamed wall structure. In MMP-9-treated grafts, microvessels appeared highly organized, forming networks in the adventitia and media. Tissue transcriptome analysis identified the growth factors VEGF, PDGF, and FGF as strongly responsive to MMP-9 overexpression ( Figure 6E ).
These data implicated active MMP-9 in the wall remodeling process, participating in several pathways. Systemically delivered MMP-9 enabled robust neoangiogenesis and, most importantly, accelerated the growth of intimal neotissue. + monocytes enable T-cell invasion through basement membrane. A, Artificial basement membranes were built by coating collagen IV and collagen I layers on top of membranes (pores, 8.0 μm). Purified T cells, monocytes, or T-cell/monocyte mixtures were layered on top of the collagen. Invasive capacity of T cells and monocytes was quantified by enumerating the cells in the lower chamber. B and C, Monocytes (100 000 per insert, B) and CD (cluster of differentiation) 4 + T cells (100 000 per insert, C) were isolated from healthy controls (HCs) and patients with giant cell arteritis (GCA) (n=8 each) and stimulated with LPS (lipopolysaccharide)/IFN-γ and anti-CD3/CD28, respectively. After 24 h, cells that had passed through collagen IV/I were counted. Unpaired 2-tailed Student t test. D, CD4 + T-cell/monocyte mixtures (100 000 each) were placed on top of the collagen gel. In each well, isotype control IgG or anti-MMP-9 antibody (10 μg/mL) was added. After 24 h, T cells that had passed through the gels were counted (n=8 each). Two-way ANOVA. All data are mean±SEM. N.S. indicates nonsignificant. *P<0.05, **P<0.01. 
Collagen Breakdown Product Acetylated ProlineGlycine-Proline Has Modest Proinflammatory Functions
Five of the 20 known MMPs, including MMP-9, degrade ECM and generate ECM protein fragments, typically called matrikines. 33 Matrikines regulate cellular activity by interacting with specific receptors and have been implicated in inflammation, immune responses, wound repair, atherosclerosis, and tumor progression. 33, 34 Proteolytic action of MMP-1, MMP-8, and MMP-9 on ECM collagen generates the tripeptide proline-glycine-proline (PGP), which is subsequently acetylated on its N-terminus (ac-PGP) and protected from degradation. 33 Ac-PGP functions as a neutrophilic chemokine. 35 GCA is not a neutrophilic inflammation, but ac-PGP has recently been involved in tissue remodeling; for example, idiopathic pulmonary fibrosis. 36 Acetylated PGP is completely protected from degradation, providing an opportunity to test in vivo whether products of MMP-9-dependent collagen breakdown amplify vessel wall inflammation. We injected ac-PGP into NOD scid gamma (NSG) mice carrying inflamed human arteries, giving a total dose of 600 μg for 2 weeks (Figure 7) . The tripeptide caused modest wall thickening in the explanted arteries, with histology showing increased density of intramural infiltrates ( Figure 7A ). Analysis of tissue-extracted mRNA demonstrated 60% higher concentrations of TCR transcripts and 3-fold higher concentrations of CD163 transcripts after ac-PGP injection ( Figure 7B ; Online Figure IV) . Immunostaining for tissueinfiltrating T cells localized the invading cells to the media ( Figure 7C ). Ac-PGP treatment modestly increased the number of tissue-invading T cells by 34% ( Figure 7D ). The collagen degradation product had mild proinflammatory functions that recapitulated those of MMP-9. IL-1β, IL-6, IFN-γ, and IL-21 were significantly higher after injection of ac-PGP, whereas tissue production of TNF-α and IL-17 were stable and unaffected by ac-PGP (Online Figure IV) . Vasculitis was induced in human artery-NSG (NOD scid gamma mice) mice, and chimeras were assigned to the vehicle, enzymatically inactive MMP-9 (iMMP-9), or rMMP-9 (recombinant MMP-9) treatment group as in Figure 5 . Intimal thickness was measured as the distance between the lamina elastic interna and the luminal endothelial lining. A, H&E (hematoxylin and eosin)-stained tissue sections from explanted arteries. Representative images. Black arrowheads mark the lamina elastic interna, and the red arrow spans the thickness of the intimal layer (scale bar=100 μm). B, Intimal layer thickness in 8 arterial grafts treated with either vehicle, iMMP-9, or rMMP-9. Lines connect data from paired samples. C, CD (cluster of differentiation) 31 + α-SMA (α-smooth muscle actin) + microvessels identified by dual-color immunostaining. Nuclei marked by DAPI (4',6-diamidino-2-phenylindole). Representative images from iMMP-9-treated and rMMP-9-treated tissues (scale bars=100 μm). D, Densities of microvessels in paired arterial grafts treated with rMMP-9 or iMMP-9 measured as in (C). Data from 8 paired arterial grafts are connected by a line. E, Tissue transcriptome of angiogenic cytokines in the explants from iMMP-9-treated and rMMP-9-treated mice. Results from 6 samples in each treatment arm. All data are mean±SEM. Paired 2-tailed Student t test. HPF indicates high-power field; and Rel. Exp., relative expression. *P<0.05, **P<0.01, ***P<0.001. These data supported moderate proinflammatory functions of the MMP-9-induced matrikine ac-PGP. Although different in extent, MMP-9 and the MMP-9-induced matrix breakdown product induced a similar inflammatory signature, upregulating IL-1β, IL-6, IFN-γ, and IL-21, whereas TNF-α and IL-17 were unaffected.
Collagen Degradation Product ac-PGP Has Minimal Effects on Maladaptive Wall Remodeling
The tripeptide PGP exerts is biological activities by binding cellular receptors on neutrophils, EC, etc, compatible with its role in chemotaxis. In lung fibrotic disease, ac-PGP is protective, 37 possibly by recruiting wound healing responses. We explored whether the 2 MMP-9-dependent pathologies, neoangiogenesis and neointimal growth, were mediated via collagen breakdown. Intimal thickening and microvascular density increased slightly by 19% and 23%, respectively, after ac-PGP injection ( Figure 7E through 7H) . Whereas MMP-9 was highly effective in amplifying vasculitis by fragmenting the elastic lamina, promoting neointimal growth, and fostering angiogenesis, the matrikine predominantly affected the intensity of tissue inflammation. An interesting discrepancy emerged between a borderline increase in microvessel formation ( Figure 7H ) combined with a marked enhancement in tissue VEGF, PDGF, and FGF in artery grafts from ac-PGP-treated animals (Online Figure  IV) . The 3 growth factors increased by 2-to 4-fold, suggesting ac-PGP-dependent effects on cells supplying these cytokines. Despite ample supply of growth factors, ac-PGP-induced induction of neoangiogenesis was minimal.
To explore similarities and dissimilarities in the disease phenotype, we directly compared the outcomes in tissue grafts from MMP-9 and ac-PGP-treated chimeras (Online Figure  IV) . To capture the impact on inflammatory lesion building, we quantified CD163-a marker of tissue-infiltrated macrophages-and assessed T-cell density. To weigh how the interventions affected neoangiogenic activity, we enumerated CD31 + α-SMA + vascular lumina. To evaluate the importance of protease activity versus matrikine production on neointima growth, we measured intimal thickness. MMP-9 and the tripeptide were equivalent in terms of forming T cell and macrophage infiltrates but were dissimilar for the maladaptive repair processes. Neoangiogenesis seemed to be the primary target of MMP-9, rising by 67%, emphasizing dependence of this process on proteolytic activity. Ac-PGP minimally affected microvessel formation and intimal hyperplasia (Online Figure V) .
In summary, there was only partial overlap in the disease phenotype produced by MMP-9 and the matrikine ac-PGP, attesting to MMP-9's pathogenic activities beyond matrix cleavage in the inflammatory lesions.
Discussion
GCA is a granulomatous vasculitis, assigning a critical role to monocytes, macrophages, and T cells in the disease process. Under physiological conditions, the wall layers of medium and large human arteries are inaccessible for inflammatory cells. Only if the immune privilege 38 is broken can cells of the innate and adaptive immune system enter the protected tissue niche and establish organized inflammatory infiltrates. In GCA, the vasculitic lesions are characterized by the recruitment and retention of multiple functional lineages of proinflammatory T cells, the activation of diverse macrophage populations, and the induction of multinucleated giant cells. Once vasculitic lesions occupy the tissue niche, the vessel wall responds with a maladaptive repair process. 39 Clues for a key role of proteases in wall remodeling derive from a histological hallmark of the arteritis, namely the fragmentation of the lamina elastic interna. Additional pathogenic events include the mobilization and migration of myofibroblasts forming hyperplastic intima and robust neoangiogenesis expanding the capillary network of the adventitia. Additional damage patterns include dissection and aneurysm formation in the aorta. Data presented here identify the metalloproteinase MMP-9 as a key player in the disease process with a notable role of MMP-9-producing monocytes outside of the vasculitic lesions that function as gate keepers by controlling access of innate and adaptive immune cells to the privileged tissue site.
Phenotypically, circulating monocyte subpopulations in patients with GCA and age-matched healthy individuals were indistinguishable, confirming earlier studies. 40 However, transcriptome analysis alerted to the predisposition of patient-derived monocytes to express abundant transcripts for MMP-2 and MMP-9. mRNA for 5 additional MMPs was present at equal amounts in GCA and control monocytes ( Figure 1E ). These data focused attention away from MMP-9 production in lesional macrophages toward circulating monocytes. Injection of an allosteric MMP-9 inhibitor-the monoclonal antibody GS-5745 that interferes with both pro-MMP-9 activation and catalysis of active MMP-9 into human artery-SCID chimeras-demonstrated robust anti-inflammatory effects of MMP-9 blockade. Antibody injection was sufficient to prevent the formation of intramural infiltrates. Suppression of IL-1β, IL-6, IFN-γ, and IL-21 in anti-MMP-9-treated artery grafts was not unexpected, given the profound reduction in tissueinfiltrating cells. A more detailed analysis of tissue-residing T cells producing IFN-γ and IL-21 confirmed that relative proportions of these 2 T-cell lineages were essentially unchanged in control-and anti-MMP-9-treated arteries, connecting the strong anti-inflammatory effects of the antibodies to the disruption of cell recruitment.
Current data identify access control to the vessel wall as a critical determinant of vasculitis susceptibility. T cells and monocytes/macrophages enter the vessel wall through adventitial vasa vasora. At the adventitia-media border, tissueinvasive T cells encounter wall-endogenous vascular dendritic cells that function as antigen-presenting cells. 41 In GCA, these vascular dendritic cells have an abnormal phenotype and lack the immunoinhibitory ligand PD-L1, 6 thus failing to curb in situ T-cell activation. Antigen recognition has been implicated in driving GCA, 42 but recent data indicate that wall-infiltrating T-cell populations are multifunctional and highly diverse; compatible with a failure in antigen-nonspecific regulation. In fully developed vasculitis, granulomatous lesions composed of T cells and macrophages occupy the vessel wall, breaching the artery's immunoprivilege-a multifaceted process that ultimately suppresses wall inflammation. 43 Instrumental in the breakdown of the immunoprivilege is a population of CD69 + CD103 + T cells that are tissue anchored and persist long term, even when influx of new T cells is prevented. 44 T cells with this phenotype are a specialized subset of tissue-resident memory T cells, believed to function as tissue-positioned sentinels. 45, 46 MMP-9 directly regulated how many T cells were able to enter and stay in the vessel wall, but further studies need to explore whether MMP-9 affects the recruitment/retention/survival of tissue-resident memory T cells.
If MMP-9 is a critical pathogenic effector molecule in GCA, as suggested by the profound antivasculitic effects of MMP-9 inhibition in the in vivo model system and circulating monocytes in patients with GCA spontaneously overexpress MMP-9, then MMP-9 + monocytes may hold a key role in the disease process. MMP-9 is recognized for its ability to cleave type IV collagen-a matrix protein enriched in basement membranes. Cell invasion into the arterial wall requires degradation of the endobasement membrane-a process we modeled in an in vitro invasion assay. MMP-9 + monocytes from patients with GCA were indeed more efficient in passing through a type IV collagen layer, but more importantly, they enabled T cells to overcome the barrier. The adoptive transfer of monocytes without T cells into the chimeric mice was insufficient to allow the entry of inflammatory cells into the medial layer and monocytes alone could not drive wall remodeling, such as intimal hyperplasia (Online Figure VI) . These data emphasized the key pathogenic role of T cells, which in turn appear entirely dependent on help provided by proteaseproducing monocytes to enter the tissue space. Overall, type IV collagen emerges as a protective shield for the arterial wall.
Beyond its dominant role in enabling a breach of the artery's immunoprivilege, MMP-9 may have additional roles within the vasculitic lesions. We confirmed the expression of pro-MMP-9 in macrophages populating the transmural infiltrates and in a subset of multinucleated giant cells. More informative were the mechanistic studies, analyzing artery explants from anti-MMP-9-treated chimeras. Enzyme activity of MMP-9 was required to guide tissue repair activities, including neoangiogenesis and neointima formation. Bioactive molecules generated by MMP-9-dependent collagen cleavage, specifically the PGP tripeptide, could only partially replace the protease as a vasculitogenic driver. The collagen breakdown product was active in assembling intramural infiltrates but was barely able to interfere with the wall remodeling process, separating the inflammatory load within the arterial wall from misguided repair activity.
Macrophage populations occupying GCA-affected blood vessels are heterogeneous. Adventitial macrophages have been described to produce IL-1β and IL-6. 47 Medial macrophages are metabolically highly active and function as production facilities, supplying enzymes (MMPs), 14 growth factors (VEGF, PDGF, and FGF), 31, 32 and tissue protective aldose reductase. 15 While not exclusive, the media typically serves as the site of granuloma assembly and close to the media-intima border, macrophages fuse to build multinucleated giant cells. Such multinucleated giant cells produce MMP-9 (Figure 1 ), optimizing local delivery. Lamina elastic interna fragmentation is a prerequisite for cell migration from distal wall sites to the intima. Notably, neointimal growth is the process that is the most significant for the patient because it causes ischemic tissue injury, such as stroke or blindness. Two weeks of vessel wall inflammation were sufficient to observe progressive intimal thickness, created by multilayering of proliferative cell populations. Cells forming the hyperplastic intima are α-SMA positive, but whether they originate from wall-resident fibroblast populations or represent phenotypically modified vascular smooth muscle cells is unknown. Macrophages are the source of growth factors, such as PDGF and FGF, needed for cell proliferation. In a recent study, T cells were implicated in controlling growth of α-SMA + cells, with enhancement of the process when T-cell function was unleashed through blocking the PD-1 checkpoint. 6 Current data separate intimal hyperplasia from the inflammatory load because ac-PGP was able to enhance crowding of tissue-invading T cells but barely affected intimal thickness.
Data for the current study have possible impact on how GCA is diagnosed and treated. The emerging disease model separates the extravascular and the vascular component of disease. For extravascular manifestations, innate cytokines seem to be important, driving an intense hepatic acute-phase response. Such cytokines are effectively suppressed by corticosteroids 11 or by directly targeting cytokines. 48 Vascular GCA seems relatively refractory to cytokine suppression, with frank vasculitis persisting in temporal arteries in patients treated for ≤1 year. 49 Therapeutic targeting of vasculitic lesions is emerging as the key challenge in management. 50 Current data strongly suggest that a single cell type and a single effector molecule critically control access for inflammatory cells to the wall. Monitoring the propensity of circulating monocytes to produce MMP-9 may provide a useful biomarker of vasculitis risk. Understanding why the patients' monocytes are biased toward MMP production long before they enter the tissue site could provide new targets to preserve the arterial wall immunoprivilege. Given the efficacy of anti-MMP-9 in providing upstream suppression of vasculitic activity, targeting this enzyme appears to provide a cytokine-independent strategy to block vessel wall inflammation. Studies are needed to explore whether anti-MMP-9 has immunosuppressive effects for normal immune responses. Available data suggest limited toxicity of inhibiting MMP-9 enzymatic activity in clinical trials. 51 Combination therapy of corticosteroids with an MMP-9 blocker may provide the optimal approach to managing all components of the vasculitic response in GCA.
